Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

INCY vs VRTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRTX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

VRTX Overall Winner 6-Pillar Tally: INCY 3 – 3 VRTX Matrix Metrics: INCY 3 – 7 VRTX

As of Nov 16, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Incyte Genomics Inc (INCY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). INCY carries a Unified Composite Score of 61.2/100 (BUY) at $120.55 (14.0x Forward P/E, 32.2% operating margin), whereas VRTX carries 37.0/100 (SELL) at $536.61 (27.0x Forward P/E, 37.8% operating margin).

  • Composite vs. Pillar Nuance: While INCY currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. VRTX 37.0/100 SELL), VRTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (37.8% vs. 32.2% operating margin) and revenue trajectory (+11.8% vs. +14.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INCY vs VRTX
INCY NASDAQ
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$120.55
-0.35% 1D
Market Cap $24.8B
TTM Revenue $6.01B
Forward P/E 14.0x
Beta / 30D Vol 0.30β · 35% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.0 · SMA20: $118.59 · SMA50: $119.04
VRTX NASDAQ Head-to-Head Winner
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$536.61
-0.37% 1D
Market Cap $137.6B
TTM Revenue $13.0B
Forward P/E 27.0x
Beta / 30D Vol 0.36β · 30% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 39.0 Fund 48.0 Flow 70.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $537.51 · SMA50: $522.15

6-Pillar Scorecard Institutional Category Breakdown (INCY 3 – 3 VRTX)

Columns: Metric · INCY · VRTX
1. Valuation Multiples INCY
Forward P/E 14.0x 27.0x
Trailing P/E 62.1x 34.9x
PEG Ratio 10.82x 2.38x
EV / Revenue 3.6x 10.7x
2. Growth & Scale INCY
Revenue Growth (YoY) +14.0% +11.8%
Earnings Growth (YoY) +37.7% -39.0%
TTM Revenue (USD) $6.01B $13.0B
Market Cap $24.8B $137.6B
3. Profitability & Quality VRTX
Gross Margin 56.0% 54.8%
Operating Margin 32.2% 37.8%
Net Profit Margin 6.7% 30.7%
Return on Equity (ROE) 7.8% 20.8%
4. Balance Sheet & Cash Flow VRTX
Cash Generation (TTM) $680M $3.20B
Cash Flow Margin 11.3% 24.7%
Net Cash / Leverage $3.24B Net Cash $1.50B Net Debt (0.31x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRTX
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 36.5% (64th %ile) 88.3% (25th %ile)
Put/Call OI Skew 1.62x (Put-Skewed) 1.42x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat INCY
OpEx & R&D Intensity 23.8% of Rev ($1.43B) 17.0% of Rev ($2.20B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INCY (3) vs VRTX (7)
Institutional Metric INCY VRTX Criterion Row Edge
Market Capitalization
Scale
$24.8B $137.6B Larger Scale VRTX
Trailing P/E Ratio
Valuation
62.1x 34.9x Lower Multiple VRTX
Forward P/E Ratio
Valuation
14.0x 27.0x Lower Multiple INCY
Revenue Growth (YoY)
Growth
+14.0% +11.8% Higher Growth INCY
Operating Margin (TTM)
Profitability
32.2% 37.8% Higher Margin VRTX
Net Profit Margin
Profitability
6.7% 30.7% Higher Margin VRTX
Return on Equity (ROE)
Capital Efficiency
7.8% 20.8% Higher ROE VRTX
52-Week Range Position
Momentum
72% ($89–$133) 80% ($412–$569) Stronger Trend VRTX
Beta / 30D Volatility
Risk Regime
0.30β · 35% Vol 0.36β · 30% Vol Lower Realized Risk VRTX
Unified Institutional Score
Composite Signal
61.2 / 100 (BUY) 37.0 / 100 (SELL) Higher Composite INCY
Trailing 12M Revenue (USD)
Operating Scale
$6.01B $13.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
56.0% 54.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.82x PEG · 3.6x EV/Rev 2.38x PEG · 10.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$680M ($3.24B Net Cash) $3.20B ($1.50B Net Debt (0.31x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VRTX +0.76 pp
INCY: +6.62% · VRTX: +7.38%
3M Horizon VRTX +3.95 pp
INCY: -2.36% · VRTX: +1.59%
6M Horizon INCY +3.73 pp
INCY: +26.64% · VRTX: +22.91%
1Y Horizon VRTX +9.13 pp
INCY: +14.36% · VRTX: +23.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INCY Revenue VRTX Revenue INCY Op. Margin VRTX Op. Margin Margin Leader
FY2018 $1.88B $3.05B 6.9% 20.8% VRTX
FY2019 $2.16B $4.16B 18.6% 28.8% VRTX
FY2020 $2.67B $6.21B -9.9% 46.0% VRTX
FY2021 $2.99B $7.57B 19.6% 36.7% VRTX
FY2022 $3.39B $8.93B 17.1% 48.2% VRTX
FY2023 $3.70B $9.87B 16.8% 38.8% VRTX
FY2024 $4.24B $11.0B 1.4% -2.1% INCY
FY2025 $5.14B $12.0B 29.5% 34.8% VRTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INCY CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 36.5%
IV Percentile 64th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRTX CONSOLIDATION
58d in phase · OBV DISTRIBUTION
Current IV 88.3%
IV Percentile 25th %ile
Put/Call OI Skew 1.42x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VRTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INCY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $24.8B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($1.43B)
90D Engineering Disclosures 0 Published
VRTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $137.6B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($2.20B)
90D Engineering Disclosures 0 Published

Investor FAQ INCY vs VRTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Incyte Genomics Inc (INCY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). INCY carries a Unified Composite Score of 61.2/100 (BUY) at $120.55 (14.0x Forward P/E, 32.2% operating margin), whereas VRTX carries 37.0/100 (SELL) at $536.61 (27.0x Forward P/E, 37.8% operating margin). Composite vs. Pillar Nuance: While INCY currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. VRTX 37.0/100 SELL), VRTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (37.8% vs. 32.2% operating margin) and revenue trajectory (+11.8% vs. +14.0% YoY).

INCY leads the Growth & Scale pillar: INCY posts +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin), compared with VRTX at +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INCY cumulative revenue shifted +173.4% while VRTX shifted +293.4%. In operating R&D and SG&A reinvestment, INCY deploys 23.8% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($2.20B) (0 disclosures) for VRTX.

INCY screens cheaper on headline valuation multiples. INCY trades at 14.0x Forward P/E, 62.1x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin), whereas VRTX trades at 27.0x Forward P/E, 34.9x Trailing P/E, 2.38x PEG, and 10.7x EV/Revenue (24.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INCY (7.8% ROE) versus VRTX (20.8% ROE) capital efficiency.

In options market volatility and institutional positioning, INCY carries 36.5% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk). By comparison, VRTX carries 88.3% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 1.42x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.36β · 30% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.